Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2025)
Candel Therapeutics (CADL) posted Change in Accured Expenses of $2.3 million for Q4 2025, up 89.49% sequentially from $1.2 million in Q3 2025, and up 320.77% YoY from $544000.0 in Q4 2024.
Candel Therapeutics (CADL) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Change in Accured Expenses for 6 years, with the latest figure at $2.3 million in Q4 2025.
- Quarterly Change in Accured Expenses rose 320.77% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (up 197.75% YoY) and the FY2025 annual result came in at $2.3 million, up 197.75% from the prior year.
- Change in Accured Expenses rose to $2.3 million in Q4 2025 per CADL's latest filing, from $1.2 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.3 million in Q4 2025 and troughed at -$2.4 million in Q1 2025.
- A 5-year average of $213600.0 and a median of $493500.0 in 2024 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses slumped 2088.89% in 2023, then soared 1692.94% in 2024.
- Over 5 years, Change in Accured Expenses stood at $719000.0 in 2021, then slumped by 39.5% to $435000.0 in 2022, then jumped by 117.47% to $946000.0 in 2023, then sank by 42.49% to $544000.0 in 2024, then surged by 320.77% to $2.3 million in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $2.3 million, $1.2 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 2.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.29 Mn |
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | -2.37 Mn |
| Mar 31, 2025 | -2.37 Mn |
| Dec 31, 2024 | 544,000.00 |
| Dec 31, 2024 | 544,000.00 |
| Sep 30, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 443,000.00 |
| Jun 30, 2024 | 443,000.00 |
| Mar 31, 2024 | -1.58 Mn |
| Mar 31, 2024 | -1.58 Mn |
| Dec 31, 2023 | 946,000.00 |
| Dec 31, 2023 | 946,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Sep 30, 2023 | -85,000.00 |